Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on December 9, 2013, regarding events occurring on December 5, 2013. The filing details the approval of the Fiscal Year 2014 Reporting Officer Performance Pay Plan by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and performance objectives rather than financial results.
Material Changes
The primary material change reported is the establishment of a new performance pay plan for fiscal year 2014 (January 1, 2014 to December 31, 2014). This plan defines specific performance objectives and pay ranges for nine reporting officers, including the CEO, President, and various Senior Vice Presidents.
Guidance, Outlook, and Management Commentary
Management has set eight specific Performance Objectives for fiscal year 2014, which include:
- Completing the phase 3 clinical trial of Aripiprazole Lauroxil and submitting a New Drug Application (NDA).
- Executing development plans for pipeline products and commercial plans for new product launches.
- Achieving financial guidance.
- Developing infrastructure to support growth and managing key business partner relationships.
Compensation Structure:
- CEO (Richard F. Pops): Target performance pay of 100% of base salary (range 0% to 200%).
- President (Shane Cooke): Target performance pay of 75% of base salary (range 0% to 150%).
- Other Participants: Target performance pay of 50% of base salary (range 0% to 100%).
Awards are contingent on active employment at the time of payment and will be distributed within two and one-half months after the end of the fiscal year. The Committee reserves the right to modify the plan or objectives during the fiscal year.
Investor Verification Checklist
- Verify the specific base salary figures for the CEO and President to calculate potential total compensation.
- Monitor the progress of the Aripiprazole Lauroxil phase 3 clinical trial and NDA submission timeline.
- Review future filings for any modifications to the Performance Objectives or payout ranges.
- Confirm the company's ability to meet the "Achieve financial guidance" objective in subsequent quarterly reports.